BACKGROUND: Familial hypobetalipoproteinaemia (FHBL) is an autosomal co-dominant hereditary disorder of lipoprotein metabolism characterised by decreased low density lipoprotein (LDL) cholesterol and apolipoprotein B (APOB) plasma levels. High levels of plasma APOB and LDL cholesterol are strong predictors for risk of cardiovascular disease (CVD), while individuals with low APOB and LDL cholesterol levels are thought to have lower than average risk for CVD, and in fact, heterozygous FHBL patients appear to be asymptomatic. METHODS: Rather than identifying truncated APOB proteins in plasma fractions separated by gel electrophoresis, which will miss any mutations in proteins smaller than 30 kb, we analysed the APOB gene directly, using PCR. RESULTS: We identified nine different mutations, six of which are novel. Each mutation showed complete co-segregation with the FHBL phenotype in the families, and statistically significant differences between carriers and non-carriers were found for plasma total, LDL, and HDL cholesterol, triglycerides, and APOB levels, but not for APOA1 levels. All carriers of an APOB mutation were completely free from CVD. CONCLUSIONS: Prolonged low levels of LDL cholesterol and elevated levels of HDL cholesterol may reduce the progression of atherosclerotic disease, but this has not been unequivocally shown that this is indeed the case in individuals with FHBL, and is the subject of a current study.
BACKGROUND:Familial hypobetalipoproteinaemia (FHBL) is an autosomal co-dominant hereditary disorder of lipoprotein metabolism characterised by decreased low density lipoprotein (LDL) cholesterol and apolipoprotein B (APOB) plasma levels. High levels of plasma APOB and LDL cholesterol are strong predictors for risk of cardiovascular disease (CVD), while individuals with low APOB and LDL cholesterol levels are thought to have lower than average risk for CVD, and in fact, heterozygous FHBLpatients appear to be asymptomatic. METHODS: Rather than identifying truncated APOB proteins in plasma fractions separated by gel electrophoresis, which will miss any mutations in proteins smaller than 30 kb, we analysed the APOB gene directly, using PCR. RESULTS: We identified nine different mutations, six of which are novel. Each mutation showed complete co-segregation with the FHBL phenotype in the families, and statistically significant differences between carriers and non-carriers were found for plasma total, LDL, and HDL cholesterol, triglycerides, and APOB levels, but not for APOA1 levels. All carriers of an APOB mutation were completely free from CVD. CONCLUSIONS: Prolonged low levels of LDL cholesterol and elevated levels of HDL cholesterol may reduce the progression of atherosclerotic disease, but this has not been unequivocally shown that this is indeed the case in individuals with FHBL, and is the subject of a current study.
Authors: M E Visser; N M Lammers; A J Nederveen; M van der Graaf; A Heerschap; M T Ackermans; H P Sauerwein; E S Stroes; M J Serlie Journal: Diabetologia Date: 2011-05-06 Impact factor: 10.122
Authors: Anne-Sophie Cloos; Laura G M Daenen; Mauriane Maja; Amaury Stommen; Juliette Vanderroost; Patrick Van Der Smissen; Minke Rab; Jan Westerink; Eric Mignolet; Yvan Larondelle; Romano Terrasi; Giulio G Muccioli; Andra C Dumitru; David Alsteens; Richard van Wijk; Donatienne Tyteca Journal: Front Physiol Date: 2021-02-23 Impact factor: 4.566
Authors: Hamed Kharrati-Koopaee; Esmaeil Ebrahimie; Mohammad Dadpasand; Ali Niazi; Rugang Tian; Ali Esmailizadeh Journal: J Genet Eng Biotechnol Date: 2021-07-08